全文获取类型
收费全文 | 10897篇 |
免费 | 588篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 137篇 |
儿科学 | 276篇 |
妇产科学 | 219篇 |
基础医学 | 1628篇 |
口腔科学 | 348篇 |
临床医学 | 1073篇 |
内科学 | 2228篇 |
皮肤病学 | 176篇 |
神经病学 | 1220篇 |
特种医学 | 187篇 |
外科学 | 943篇 |
综合类 | 39篇 |
一般理论 | 5篇 |
预防医学 | 1165篇 |
眼科学 | 106篇 |
药学 | 939篇 |
中国医学 | 57篇 |
肿瘤学 | 796篇 |
出版年
2024年 | 9篇 |
2023年 | 85篇 |
2022年 | 238篇 |
2021年 | 423篇 |
2020年 | 263篇 |
2019年 | 359篇 |
2018年 | 388篇 |
2017年 | 278篇 |
2016年 | 276篇 |
2015年 | 331篇 |
2014年 | 498篇 |
2013年 | 603篇 |
2012年 | 933篇 |
2011年 | 984篇 |
2010年 | 489篇 |
2009年 | 443篇 |
2008年 | 700篇 |
2007年 | 752篇 |
2006年 | 622篇 |
2005年 | 614篇 |
2004年 | 568篇 |
2003年 | 481篇 |
2002年 | 445篇 |
2001年 | 52篇 |
2000年 | 35篇 |
1999年 | 55篇 |
1998年 | 87篇 |
1997年 | 75篇 |
1996年 | 50篇 |
1995年 | 49篇 |
1994年 | 49篇 |
1993年 | 38篇 |
1992年 | 30篇 |
1991年 | 27篇 |
1990年 | 24篇 |
1989年 | 15篇 |
1988年 | 13篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 15篇 |
1984年 | 14篇 |
1983年 | 11篇 |
1982年 | 19篇 |
1981年 | 14篇 |
1980年 | 11篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1976年 | 8篇 |
1973年 | 4篇 |
1968年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management 总被引:21,自引:0,他引:21
Lok AS Zoulim F Locarnini S Bartholomeusz A Ghany MG Pawlotsky JM Liaw YF Mizokami M Kuiken C;Hepatitis B Virus Drug Resistance Working Group 《Hepatology (Baltimore, Md.)》2007,46(1):254-265
Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. 相似文献
992.
Gleeson H Barreto ES Salvatori R Costa L Oliveira CR Pereira RM Clayton P Aguiar-Oliveira MH 《Clinical endocrinology》2007,66(4):466-474
BACKGROUND: The interpretation of the true effect of GH replacement therapy (GHRT) on metabolic status in GH deficiency (GHD) is often complicated by differing aetiologies of GHD and by the presence of additional hormone deficits. OBJECTIVE: To study the growth and response of the lipid profile and body composition to GHRT in a cohort of children with the same mutation in the GHRH receptor gene. Design Nine GH-deficient subjects (mean age 12.8 years, range 5-17.5 years; three male) in a rural community in Northeast Brazil were treated with GHRT for 2 years and compared with indigenous normal controls. MAIN OUTCOME MEASURES: Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and body composition were measured at baseline and after 3, 12 and 24 months of GHRT. RESULTS: At baseline, the subjects with GHD had an adverse lipid profile, including elevated TC, elevated LDL-C and elevated TG. GHRT normalized TG in 3 months, LDL-C in 12 months and TC in 24 months. At baseline, older pubertal subjects with GHD had adverse body composition, including higher percentage fat mass (%FM), and GHRT induced a reduction in %FM that was maintained after 24 months. By contrast, younger prepubertal subjects did not have an adverse body composition. CONCLUSIONS: Lipid profile was abnormal at baseline, while abnormal body composition was only seen in older subjects in late puberty, indicating that body composition is less sensitive to the effect of GHD than lipid profile. GHRT improves lipid profile at all ages, while it affects body composition only towards the end of growth, emphasizing its importance in achieving normal somatic development in the transition period. 相似文献
993.
Noto A Zahradka P Ryz NR Yurkova N Xie X Taylor CG 《Metabolism: clinical and experimental》2007,56(1):142-151
Pancreatic preservation is an important part of diabetes management that may occur with improved peripheral insulin sensitivity and attenuated low-grade adipose tissue inflammation. The objective of the current study was to determine the response of obese, insulin-resistant fa/fa Zucker rats vs lean controls to dietary conjugated linoleic acid (CLA) supplementation with respect to pancreatic islet size, insulin resistance, and markers of inflammation and adipose glucose uptake. Six-week-old fa/fa and lean Zucker rats (n = 20 per genotype) were fed either a 1.5% CLA mixture or control diet for 8 weeks. Oral glucose tolerance testing was conducted at 7.5 weeks. Fasting serum haptoglobin, insulin, and C-peptide were assayed, and select messenger RNA (mRNA) and protein markers of inflammation and glucose metabolism were measured in adipose and liver tissues. CLA-fed fa/fa Zucker rats had smaller islet cell size, improved oral glucose tolerance and insulinemia, and attenuated serum haptoglobin levels compared with control-fed fa/fa Zucker rats, despite no differences in body weight and a slightly higher visceral adipose mass. CLA did not alter insulin sensitivity or islet size in lean Zucker rats. The CLA-fed fa/fa rats also had greater adipose glucose transporter-4 mRNA and less adipose tumor necrosis factor alpha mRNA and protein compared with control-fed fa/fa rats. In contrast, other markers of inflammation and glucose metabolism including adipose macrophage inflammatory factor, macrophage inflammatory protein-2, and liver pyruvate carboxylase and pyruvate dehydrogenase kinase 4 were not significantly changed. These results suggest that CLA supplementation preserved pancreatic function in conjunction with improved peripheral glucose use and reduced inflammation in fa/fa Zucker rats. 相似文献
994.
Pereira RM Aguiar-Oliveira MH Sagazio A Oliveira CR Oliveira FT Campos VC Farias CT Vicente TA Gois MB Oliveira JL Marques-Santos C Rocha IE Barreto-Filho JA Salvatori R 《The Journal of clinical endocrinology and metabolism》2007,92(6):2353-2357
CONTEXT: Biallelic mutations in the GHRH receptor (GHRHR) gene (GHRHR) are a frequent cause of isolated GH deficiency (IGHD). Although heterozygous carriers of these mutations appear normal, we hypothesized that heterozygosity for a GHRHR mutation might be associated with a subclinical phenotype. METHODS: We studied members of a large Brazilian kindred with IGHD (Itabaianinha cohort) caused by a homozygous null GHRHR mutation. We compared 76 adult subjects (age, 25-75 yr) heterozygous for the mutation (WT/MT) with 77 sex-matched controls from the same population who are homozygous for the wild-type GHRHR allele (WT/WT). RESULTS: We found no difference in adult height and sd score for serum IGF-I between the two groups. Body weight, body mass index, skin folds, waist and hip circumferences, and lean mass were all reduced in WT/MT subjects. Percentage fat mass and waist/hip ratio were similar in the two groups. Fasting insulin and homeostasis model assessment of insulin resistance were lower in WT/MT. The other biochemical parameters [total and fractionated cholesterol, triglycerides, lipoprotein (a), and C-reactive protein] were not different between the two groups. CONCLUSIONS: Heterozygosity for a null GHRHR mutation is not associated with reduction in adult stature or in serum IGF-I but is associated with changes in body composition and possibly an increase in insulin sensitivity. These effects do not seem to be modulated by changes in circulating IGF-I. 相似文献
995.
Diana G Valentini G Travaglione S Falzano L Pieri M Zona C Meschini S Fabbri A Fiorentini C 《Proceedings of the National Academy of Sciences of the United States of America》2007,104(2):636-641
The mechanism whereby the morphology and connectivity of the dendritic tree is regulated depends on an actin dynamics that, in turn, is controlled by Rho GTPases, a family of small GTP-binding proteins encompassing Rho, Rac, and Cdc42 subfamilies. Cytotoxic necrotizing factor 1 (CNF1), a protein toxin from Escherichia coli, constitutively activates Rho GTPases, thus leading to remodeling of the actin cytoskeleton in intact cells. Here, we show that the modulation of cerebral RhoA and Rac1 activity induced by CNF1 in mice leads to (i) rearrangement of cerebral actin cytoskeleton, (ii) enhanced neurotransmission and synaptic plasticity, and (iii) improved learning and memory in various behavioral tasks. The effects persist for weeks and are not observed in mice treated with a recombinant CNF1, in which the enzymatic activity was abolished by substituting serine to cysteine at position 866. The results suggest that learning ability can be improved through pharmacological manipulation of neural connectivity. 相似文献
996.
997.
998.
999.
Cuspidi C Meani S Valerio C Sala C Fusi V Zanchetti A Mancia G 《American journal of hypertension》2007,20(3):296-303
OBJECTIVE: We sought to investigate the association of the metabolic syndrome (MS) with cardiovascular alterations in essential hypertensives in relation to age. METHODS: A total of 3266 untreated and treated hypertensive patients categorized in three age groups (I: 17 to 40 years; II: 41 to 64 years; III: >64 years) were considered for this analysis. All patients underwent extensive investigations searching for target organ damage (TOD). The MS was defined according to Advanced Technology Laboratories (ATP) III criteria. RESULTS: In the entire population, the risk of left ventricular hypertrophy (LVH), carotid abnormalities, and microalbuminuria increased by 2.5 (P = .003), 2.2 (P = .005), and 1.5 times (P = .01), respectively, in the presence of MS after adjusting for several confounders. Prevalence of LVH (group I: 39% v 22%; group II: 53% v 35%; group III: 69% v 52%, P < .01 for all), carotid thickening (group I: 8% v 2%; group II 29% v 19%; group III: 69% v 52%, P < .05 for all) and microalbuminuria (group I: 20% v 11%; group II: 16% v 8%; group III: 18% v 11%, P = .05 for all) was significantly higher in patients with MS than in their counterparts across all age groups. CONCLUSIONS: In hypertensive patients the MS amplifies TOD regardless of patient's age, thus increasing cardiovascular risk. This synergistic effect may accelerate the early development of TOD in young hypertensives and enhance the age-associated cardiovascular alterations in the elderly. 相似文献
1000.
This study examines the relationship between coping styles, quality of life, and depressive symptoms in older heart failure patients. Eighty heart failure patients seeking treatment in an outpatient heart failure or family practice clinic participated in a study examining depression, disability, and heart failure. Patients completed a clinical interview and questionnaires about mood, functional impairment, comorbid illness, quality of life, and coping. Heart failure severity and maladaptive coping styles, including denial, self-distraction, and self-blame, negatively affected quality of life and depressive symptoms. The use of maladaptive coping strategies involves efforts that divert attention from the illness and suggests the need to provide heart failure patients the skills to directly address the stress associated with their illness. Interventions that target these coping strategies may help patients take a more active role in their heart failure management and may improve psychological and cardiac outcomes. 相似文献